Century Therapeutics (IPSC) is a pre-revenue clinical-stage iPSC cell therapy company. As of March 31, 2026, the MFFAIS liquidation value is reported at negative $42.2 million, reflecting the structural asymmetry of a development-stage biotech: haircut assets yield less than face-value liabilities. The primary recovery asset is the cash and investment portfolio. The company disclosed $51.0 million in cash and cash equivalents and $165.9 million in investments as of March 31, 2026, totaling $217.0 million in liquid assets. Under the liquidation lens, cash receives a 100% recovery haircut (face value), and short-duration fixed-maturity securities receive close to par, making this the dominant recoverable asset class. PP&E is modest — depreciation ran at approximately $3.0 million in Q1 2026, and the company holds cGMP lab and office facilities primarily under operating leases rather than owned assets. PP&E at a 50-70% haircut is therefore a small contributor. All intangible assets (iPSC platform IP, licenses from FCDI, Catalent, iCELL) carry zero liquidation value under standard methodology. The liability stack is the key constraint. Operating lease obligations total $69.2 million undiscounted through the end of the lease terms (per the contractual obligations table: $8.7M within 1 year, $18.0M 1-3 years, $18.7M 3-5 years, $23.9M beyond 5 years). These obligations do not extinguish on windup and sit at face value in a liquidation scenario. The company carries no funded debt. Accumulated deficit stands at $813.6 million as of March 31, 2026. The most significant balance sheet change since the prior filing (FY2025 10-K) is the January 2026 private placement, which closed January 9, 2026 and injected approximately $126.4 million net proceeds. This raised total liquid assets materially — prior to the placement, the company entered 2026 with a substantially smaller cash position — and extends the disclosed runway into Q1 2029. The BMS collaboration (the sole historical revenue source) terminated March 12, 2025; zero collaboration revenue was recognized in Q1 2026 versus $109.2 million in Q1 2025, the latter representing the entire remaining deferred revenue balance recognized upon termination. Current quarterly cash burn from operations was approximately $25.3 million in Q1 2026. The negative liquidation value from MFFAIS ($42.2M negative) is directionally consistent with the filing data: liquid assets of ~$217M less operating lease obligations at face value (~$69M), residual PP&E at a haircut, and working capital liabilities, with further reduction from any wind-down costs not separately quantified. The filing does not separately XBRL-tag the balance sheet at the individual line-item level in the TAG_CONTEXT provided (TAG_CONTEXT is empty), so no individual balance-sheet tags can be surfaced in tag_insights. The operating lease commitment schedule is disclosed in MD&A narrative but is not separately tagged in XBRL. The contingent consideration liability (remeasured, generating a $1.8M gain in Q1 2026) and the milestone/royalty payment obligations under FCDI, Catalent, and iCELL agreements are contingent and excluded from the contractual obligations table; these represent tail liabilities that would need to be negotiated or extinguished in a wind-down. The common stock warrant overhang from the January 2026 private placement (71.4 million warrants at a $2.60 exercise price, expiring 30 days after initial Phase 1 CNTY-813 data or the third anniversary of closing) is equity-classified and does not affect the liability stack.
▼ Community Notes